Navigation Links
Collagen Meniscus Implant

ProductsCollagen Meniscus Implant
Company ReGen Biologics
Item Collagen Meniscus Implant
Features 
  • A type I collagen implant designed for patients with an irreparable meniscus tear or loss of meniscus tissue
  • The purpose of the CMI is to assist patients to regain mobility and return to a more vigorous lifestyle, while forestalling or minimizing degenerative joint disease.
  • Assists the body to generate new tissue, which replaces the damaged meniscus tissue removed by the surgeon.
  • The result is designed to provide patients with increased mobility and a return to a more active lifestyle.
  • Description The Collagen Meniscus Implant (CMI) is a type I collagen implant designed for patients with an irreparable meniscus tear or loss of meniscus tissue, typically through an arthroscopic partial meniscectomy procedure. The purpose of the CMI is to assist patients to regain mobility and return to a more vigorous lifestyle, while forestalling or minimizing degenerative joint disease. The Collagen Meniscus Implant is a method of regenerating meniscus tissue using the body's own healing process. A next generation approach to tissue repair, the CMI assists the body to generate new tissue, which replaces the damaged meniscus tissue removed by the surgeon. The result is designed to provide patients with increased mobility and a return to a more active lifestyle. The CMI is a resorbable type I collagen scaffold designed to minimize progressive degenerative changes in the knee after a partial meniscectomy by providing an alternative to the permanent loss of meniscus tissue. The CMI is similar to the natural shape of the meniscus and it is made of highly purified collagen, the most commonly found protein in the body. In cases where meniscus tissue cannot be repaired by suturing, the damaged tissue is removed and the CMI is sutured in place filling the defect where tissue is missing. Once sutured in place, the CMI provides a matrix into which the body's own cells may begin to move or migrate. New meniscus tissue is formed as these cells migrate and multiply. As this tissue regeneration takes place, the CMI is absorbed by the body. The regenerated tissue has the potential to restore function, reduce pain, and possibily suspend the degenerative process that begins with the loss of meniscus tissue. The CMI is made of type I collagen and it is a biocompatible, bioresorbable material that is designed to provide a scaffold for tissue growth when implanted in the knee. The surgeon sutures the CMI into the area where the meniscus tissue is missing. Once implanted, the CMI's highly porous matrix allows cellular ingrowth from the patient's own cells. This process regenerates meniscus tissue which provides the potential for restoring function, reducing pain and possibly arresting the degenerative process that begins with the loss of meniscus tissue.
    Info ReGen Biologics
    Customer Service: (201) 651-5140
    Web site: http://www.regenbio.com

    Related medicine products :

    1. Temporary Collagen Plugs
    2. Ultrafoam Collagen Sponge
    3. UltraPlug Collagen Absorbably Punctal Plugs
    4. INSTAT Collagen Absorbable Hemostat
    5. Pelvicol Acellular Collagen Matrix (Continence)
    6. Contigen Bard Collagen Implant
    7. Pelvicol® Acellular Collagen Matrix
    8. PelviSoft® Acellular Collagen BioMesh
    9. Hydrix XM Collagen Matrix
    10. Zyderm® and Zyplast® Injectable Collagen Implants
    11. CosmoDerm®and CosmoPlast® Collagen Replacement Therapy®
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products:
    (Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
    (Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
    Breaking Medicine News(10 mins):
    (Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
    (Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
    (Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
    Breaking Medicine Technology: